Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6458607 | 1.00 | LMNA (0.55) | LMNAKDM4ESMN1; SMN2MAPTRAB9A | |
| SCHEMBL6463284 | 0.87 | SMN1; SMN2 (0.57) | LMNAKDM4ESMN1; SMN2MAPTADRA2A | |
| SCHEMBL6463274 | 0.87 | SMN1; SMN2 (0.57) | LMNAKDM4ESMN1; SMN2MAPTADRA2A | |
| SCHEMBL6459395 | 0.83 | SMN1; SMN2 (0.62) | LMNAKDM4ESMN1; SMN2MAPTRAB9A | |
| SCHEMBL6459407 | 0.83 | SMN1; SMN2 (0.62) | LMNAKDM4ESMN1; SMN2MAPTRAB9A | |
| SCHEMBL6458000 | 0.82 | LMNA (0.59) | LMNAKDM4ESMN1; SMN2MAPTRAB9A | |
| SCHEMBL6458010 | 0.82 | LMNA (0.59) | LMNAKDM4ESMN1; SMN2MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL6457804 | 0.81 | LMNA (0.58) | LMNAKDM4ESMN1; SMN2MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL6457796 | 0.81 | LMNA (0.58) | LMNAKDM4ESMN1; SMN2MAPTRAB9A | |
| SCHEMBL6462123 | 0.81 | LMNA (0.58) | LMNAKDM4ESMN1; SMN2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | LMNA 3391/4885KDM4E 1190/4885SMN1; SMN2 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.